HIV associated nephropathy epidemiology and demographics: Difference between revisions
No edit summary |
No edit summary |
||
| Line 6: | Line 6: | ||
HIV-associated nephropathy (HIVAN) is mostly seen in male patients and of African decent. The [[prevalence]] of HIVAN in the population of patients with African descent has been reported to be 3% to 12%. | HIV-associated nephropathy (HIVAN) is mostly seen in male patients and of African decent. The [[prevalence]] of HIVAN in the population of patients with African descent has been reported to be 3% to 12%. | ||
==Epidemiology== | ==Epidemiology== | ||
The [[prevalence]] of HIV-associated nephropathy (HIVAN) in the population of patients with African descent has been reported to be 3% to 12%.<ref name="pmid29224373">{{cite journal| author=Menez S, Hanouneh M, McMahon BA, Fine DM, Atta MG| title=Pharmacotherapy and treatment options for HIV-associated nephropathy. | journal=Expert Opin Pharmacother | year= 2018 | volume= 19 | issue= 1 | pages= 39-48 | pmid=29224373 | doi=10.1080/14656566.2017.1416099 | pmc=6381591 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=29224373 }} </ref> | The [[prevalence]] of HIV-associated nephropathy (HIVAN) in the population of patients with African descent has been reported to be 3% to 12%.<ref name="pmid29224373">{{cite journal| author=Menez S, Hanouneh M, McMahon BA, Fine DM, Atta MG| title=Pharmacotherapy and treatment options for HIV-associated nephropathy. | journal=Expert Opin Pharmacother | year= 2018 | volume= 19 | issue= 1 | pages= 39-48 | pmid=29224373 | doi=10.1080/14656566.2017.1416099 | pmc=6381591 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=29224373 }} </ref> | ||
==Demographics== | ==Demographics== | ||
Revision as of 12:04, 30 June 2020
|
HIV associated nephropathy Microchapters |
|
Differentiating HIV associated nephropathy from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
HIV associated nephropathy epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of HIV associated nephropathy epidemiology and demographics |
|
FDA on HIV associated nephropathy epidemiology and demographics |
|
CDC on HIV associated nephropathy epidemiology and demographics |
|
HIV associated nephropathy epidemiology and demographics in the news |
|
Blogs on HIV associated nephropathy epidemiology and demographics |
|
Risk calculators and risk factors for HIV associated nephropathy epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Ali Poyan Mehr, M.D. [2];Associate Editor(s)-in-Chief: Shakiba Hassanzadeh, MD[3]Krzysztof Wierzbicki M.D. [4]
Overview
HIV-associated nephropathy (HIVAN) is mostly seen in male patients and of African decent. The prevalence of HIVAN in the population of patients with African descent has been reported to be 3% to 12%.
Epidemiology
The prevalence of HIV-associated nephropathy (HIVAN) in the population of patients with African descent has been reported to be 3% to 12%.[1]
Demographics
Age
The average age at which patients are affected with HIV-associated nephropathy has been reported to be around 40.8 years of age in a study.[2]
Gender
HIV-associated nephropathy affects men more than women.[2]
Race
HIVAN is mostly seen in patients of African descent.[2]
References
- ↑ Menez S, Hanouneh M, McMahon BA, Fine DM, Atta MG (2018). "Pharmacotherapy and treatment options for HIV-associated nephropathy". Expert Opin Pharmacother. 19 (1): 39–48. doi:10.1080/14656566.2017.1416099. PMC 6381591. PMID 29224373.
- ↑ 2.0 2.1 2.2 Atta MG, Lucas GM, Fine DM (2008). "HIV-associated nephropathy: epidemiology, pathogenesis, diagnosis and management". Expert Rev Anti Infect Ther. 6 (3): 365–71. doi:10.1586/14787210.6.3.365. PMID 18588500.